A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma

Br J Haematol. 2021 Jun;193(5):1001-1004. doi: 10.1111/bjh.17255. Epub 2021 May 3.

Authors

Affiliations

¹ Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
² Department of Internal Medicine, Section of Hematology and Oncology, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
³ Human Genetics Laboratory, Munroe-Meyer Institute, University of Nebraska Medical Center, Omaha, NE, USA.

PMID: 33942298
DOI: 10.1111/bjh.17255

No abstract available

Keywords: DLBCL; MYC-non-IG fusion; treatment resistance.

Publication types

Case Reports
Letter

MeSH terms

Cytidine Deaminase / genetics*
Female
Humans
Lymphoma, Large B-Cell, Diffuse / genetics*
Middle Aged
Oncogene Proteins, Fusion / genetics*
Proto-Oncogene Proteins c-myc / genetics*

Substances

MYC protein, human
Oncogene Proteins, Fusion
Proto-Oncogene Proteins c-myc
AICDA (activation-induced cytidine deaminase)
Cytidine Deaminase

Associated data

ClinicalTrials.gov/NCT01431209